Treatment of deep venous thrombosis in pregnant women
The recommended dosage of tinzaparin in the treatment of thromboembolism during pregnancy is 175 IU/kg/day, as for non-pregnant subjects. In clinical practice, we have experienced a need for a higher dosage, especially in the initial phase of the treatment of deep vein thrombosis, based on four-hour...
Gespeichert in:
| Veröffentlicht in: | Acta obstetricia et gynecologica Scandinavica 2008-01, Vol.87 (11), p.1248-1251 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1251 |
|---|---|
| container_issue | 11 |
| container_start_page | 1248 |
| container_title | Acta obstetricia et gynecologica Scandinavica |
| container_volume | 87 |
| creator | Lykke, Jacob A. Grønlykke, Thor Langhoff-Roos, Jens |
| description | The recommended dosage of tinzaparin in the treatment of thromboembolism during pregnancy is 175 IU/kg/day, as for non-pregnant subjects. In clinical practice, we have experienced a need for a higher dosage, especially in the initial phase of the treatment of deep vein thrombosis, based on four-hour post-dose measurements of anti-Xa activity.
Twenty-two pregnant patients with a confirmed deep venous thrombosis were treated with tinzaparin either in a once- or twice-daily regimen. Four-hour post-dosage plasma anti-Xa activity was measured in 357 sequential blood samples during treatment. An higher dosage than recommended, was required to maintain anti-Xa activity in the target range. We suggest that the starting dosage should be 250 IU/kg/day in a twice-daily regimen, and that the dose in the initial phase be adjusted by daily monitoring of anti-Xa. |
| doi_str_mv | 10.1080/00016340802449118 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69807972</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69807972</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5082-9438b29dcbae0df5a5d627eef34257fe41e211b15cb6b501fe16e7446b97ee513</originalsourceid><addsrcrecordid>eNqF0U1v1DAQBmALgei28AO4oFzgFurxd8SptN2lUkUlVAQ3y0nGbEoSb-1sS_89XjYqByQ42Zafd2yPCXkF9B1QQ48ppaC4yFMmRAVgnpAFKEpLKoA9JYvdfplBdUAOU7rJK6aFeU4OwBhJOWcLIq8jumnAcSqCL1rETXGHY9imYlrHMNQhdanoxmIT8fvosroPGb8gz7zrE76cxyPyZXl-ffqxvLxaXZyeXJaNpIaVleCmZlXb1A5p66WTrWIa0XPBpPYoABlADbKpVS0peASFWghVV1lJ4Efk7b7uJobbLabJDl1qsO_diPmOVlWG6kqzDGEPmxhSiujtJnaDiw8WqN31yv7Vq5x5PRff1gO2fxJzczJ4MwOXGtf76MamS4-O0YobLXeF5N7ddz0-_P9ke3K1Ur8vXe5zXZrw52POxR9Waa6l_fppZVdn_NtSLz_Yz9m_n_3oQxzcGl0_rRsX0d6EbRzzT_zjub8A6y-gfA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69807972</pqid></control><display><type>article</type><title>Treatment of deep venous thrombosis in pregnant women</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lykke, Jacob A. ; Grønlykke, Thor ; Langhoff-Roos, Jens</creator><creatorcontrib>Lykke, Jacob A. ; Grønlykke, Thor ; Langhoff-Roos, Jens</creatorcontrib><description>The recommended dosage of tinzaparin in the treatment of thromboembolism during pregnancy is 175 IU/kg/day, as for non-pregnant subjects. In clinical practice, we have experienced a need for a higher dosage, especially in the initial phase of the treatment of deep vein thrombosis, based on four-hour post-dose measurements of anti-Xa activity.
Twenty-two pregnant patients with a confirmed deep venous thrombosis were treated with tinzaparin either in a once- or twice-daily regimen. Four-hour post-dosage plasma anti-Xa activity was measured in 357 sequential blood samples during treatment. An higher dosage than recommended, was required to maintain anti-Xa activity in the target range. We suggest that the starting dosage should be 250 IU/kg/day in a twice-daily regimen, and that the dose in the initial phase be adjusted by daily monitoring of anti-Xa.</description><identifier>ISSN: 0001-6349</identifier><identifier>EISSN: 1600-0412</identifier><identifier>DOI: 10.1080/00016340802449118</identifier><identifier>PMID: 18850332</identifier><identifier>CODEN: AOGSAE</identifier><language>eng</language><publisher>Oxford, UK: Informa UK Ltd</publisher><subject>Adult ; Biological and medical sciences ; deep venous thrombosis ; Dose-Response Relationship, Drug ; Factor Xa Inhibitors ; Female ; Fibrinolytic Agents - therapeutic use ; Gestational Age ; Gynecology. Andrology. Obstetrics ; Heparin, Low-Molecular-Weight - therapeutic use ; Humans ; Medical sciences ; Parity ; Pregnancy ; Pregnancy Complications, Cardiovascular - drug therapy ; Pregnancy Outcome ; Retrospective Studies ; Risk Assessment ; treatment ; Treatment Outcome ; Venous Thrombosis - drug therapy</subject><ispartof>Acta obstetricia et gynecologica Scandinavica, 2008-01, Vol.87 (11), p.1248-1251</ispartof><rights>2008 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2008</rights><rights>Acta Obstet Gynecol Scand 2008</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5082-9438b29dcbae0df5a5d627eef34257fe41e211b15cb6b501fe16e7446b97ee513</citedby><cites>FETCH-LOGICAL-c5082-9438b29dcbae0df5a5d627eef34257fe41e211b15cb6b501fe16e7446b97ee513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1080%2F00016340802449118$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1080%2F00016340802449118$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20938758$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18850332$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lykke, Jacob A.</creatorcontrib><creatorcontrib>Grønlykke, Thor</creatorcontrib><creatorcontrib>Langhoff-Roos, Jens</creatorcontrib><title>Treatment of deep venous thrombosis in pregnant women</title><title>Acta obstetricia et gynecologica Scandinavica</title><addtitle>Acta Obstet Gynecol Scand</addtitle><description>The recommended dosage of tinzaparin in the treatment of thromboembolism during pregnancy is 175 IU/kg/day, as for non-pregnant subjects. In clinical practice, we have experienced a need for a higher dosage, especially in the initial phase of the treatment of deep vein thrombosis, based on four-hour post-dose measurements of anti-Xa activity.
Twenty-two pregnant patients with a confirmed deep venous thrombosis were treated with tinzaparin either in a once- or twice-daily regimen. Four-hour post-dosage plasma anti-Xa activity was measured in 357 sequential blood samples during treatment. An higher dosage than recommended, was required to maintain anti-Xa activity in the target range. We suggest that the starting dosage should be 250 IU/kg/day in a twice-daily regimen, and that the dose in the initial phase be adjusted by daily monitoring of anti-Xa.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>deep venous thrombosis</subject><subject>Dose-Response Relationship, Drug</subject><subject>Factor Xa Inhibitors</subject><subject>Female</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Gestational Age</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Heparin, Low-Molecular-Weight - therapeutic use</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Parity</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Cardiovascular - drug therapy</subject><subject>Pregnancy Outcome</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>treatment</subject><subject>Treatment Outcome</subject><subject>Venous Thrombosis - drug therapy</subject><issn>0001-6349</issn><issn>1600-0412</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U1v1DAQBmALgei28AO4oFzgFurxd8SptN2lUkUlVAQ3y0nGbEoSb-1sS_89XjYqByQ42Zafd2yPCXkF9B1QQ48ppaC4yFMmRAVgnpAFKEpLKoA9JYvdfplBdUAOU7rJK6aFeU4OwBhJOWcLIq8jumnAcSqCL1rETXGHY9imYlrHMNQhdanoxmIT8fvosroPGb8gz7zrE76cxyPyZXl-ffqxvLxaXZyeXJaNpIaVleCmZlXb1A5p66WTrWIa0XPBpPYoABlADbKpVS0peASFWghVV1lJ4Efk7b7uJobbLabJDl1qsO_diPmOVlWG6kqzDGEPmxhSiujtJnaDiw8WqN31yv7Vq5x5PRff1gO2fxJzczJ4MwOXGtf76MamS4-O0YobLXeF5N7ddz0-_P9ke3K1Ur8vXe5zXZrw52POxR9Waa6l_fppZVdn_NtSLz_Yz9m_n_3oQxzcGl0_rRsX0d6EbRzzT_zjub8A6y-gfA</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Lykke, Jacob A.</creator><creator>Grønlykke, Thor</creator><creator>Langhoff-Roos, Jens</creator><general>Informa UK Ltd</general><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>Treatment of deep venous thrombosis in pregnant women</title><author>Lykke, Jacob A. ; Grønlykke, Thor ; Langhoff-Roos, Jens</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5082-9438b29dcbae0df5a5d627eef34257fe41e211b15cb6b501fe16e7446b97ee513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>deep venous thrombosis</topic><topic>Dose-Response Relationship, Drug</topic><topic>Factor Xa Inhibitors</topic><topic>Female</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Gestational Age</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Heparin, Low-Molecular-Weight - therapeutic use</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Parity</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Cardiovascular - drug therapy</topic><topic>Pregnancy Outcome</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>treatment</topic><topic>Treatment Outcome</topic><topic>Venous Thrombosis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lykke, Jacob A.</creatorcontrib><creatorcontrib>Grønlykke, Thor</creatorcontrib><creatorcontrib>Langhoff-Roos, Jens</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta obstetricia et gynecologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lykke, Jacob A.</au><au>Grønlykke, Thor</au><au>Langhoff-Roos, Jens</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of deep venous thrombosis in pregnant women</atitle><jtitle>Acta obstetricia et gynecologica Scandinavica</jtitle><addtitle>Acta Obstet Gynecol Scand</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>87</volume><issue>11</issue><spage>1248</spage><epage>1251</epage><pages>1248-1251</pages><issn>0001-6349</issn><eissn>1600-0412</eissn><coden>AOGSAE</coden><abstract>The recommended dosage of tinzaparin in the treatment of thromboembolism during pregnancy is 175 IU/kg/day, as for non-pregnant subjects. In clinical practice, we have experienced a need for a higher dosage, especially in the initial phase of the treatment of deep vein thrombosis, based on four-hour post-dose measurements of anti-Xa activity.
Twenty-two pregnant patients with a confirmed deep venous thrombosis were treated with tinzaparin either in a once- or twice-daily regimen. Four-hour post-dosage plasma anti-Xa activity was measured in 357 sequential blood samples during treatment. An higher dosage than recommended, was required to maintain anti-Xa activity in the target range. We suggest that the starting dosage should be 250 IU/kg/day in a twice-daily regimen, and that the dose in the initial phase be adjusted by daily monitoring of anti-Xa.</abstract><cop>Oxford, UK</cop><pub>Informa UK Ltd</pub><pmid>18850332</pmid><doi>10.1080/00016340802449118</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6349 |
| ispartof | Acta obstetricia et gynecologica Scandinavica, 2008-01, Vol.87 (11), p.1248-1251 |
| issn | 0001-6349 1600-0412 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69807972 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Biological and medical sciences deep venous thrombosis Dose-Response Relationship, Drug Factor Xa Inhibitors Female Fibrinolytic Agents - therapeutic use Gestational Age Gynecology. Andrology. Obstetrics Heparin, Low-Molecular-Weight - therapeutic use Humans Medical sciences Parity Pregnancy Pregnancy Complications, Cardiovascular - drug therapy Pregnancy Outcome Retrospective Studies Risk Assessment treatment Treatment Outcome Venous Thrombosis - drug therapy |
| title | Treatment of deep venous thrombosis in pregnant women |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A30%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20deep%20venous%20thrombosis%20in%20pregnant%20women&rft.jtitle=Acta%20obstetricia%20et%20gynecologica%20Scandinavica&rft.au=Lykke,%20Jacob%20A.&rft.date=2008-01-01&rft.volume=87&rft.issue=11&rft.spage=1248&rft.epage=1251&rft.pages=1248-1251&rft.issn=0001-6349&rft.eissn=1600-0412&rft.coden=AOGSAE&rft_id=info:doi/10.1080/00016340802449118&rft_dat=%3Cproquest_cross%3E69807972%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69807972&rft_id=info:pmid/18850332&rfr_iscdi=true |